clinical trial · NCT05242471
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease
Janssen Research & Development, LLC·phase2·active not recruiting·n = 703
Crohn's DiseaseGuselkumabGolimumabJNJ-78934804Placebo
brief summary
The purpose of this study is to evaluate the efficacy of JNJ-78934804 at Week 48 compared to guselkumab and golimumab.
started
Jul 22, 2022
primary completion
May 23, 2025
completion
Nov 5, 2029
last updated
Apr 13, 2026
official title
A Phase 2b Randomized, Double-blind, Active-and Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Induction and Maintenance Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol